Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Marcus Laird Forrest
University of Kansas Lawrence, Department: Pharmacology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Hafion, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Hafion, LLC is a subcontract on this project and is tasked with the production of a conjugate to be used in the vaccine development. Dr. Forrest is Co-Investigator on this project. He is the Chief Operations Officer with Hafion. Dr. Forrest’s spouse owns equity in the Entity. Hafion may be interested in licensing technology developed from this project in the future. This project was included in Dr. Forrest’s management plan to ensure appropriate separation between University and company role and resources.
Vaccines to counter emerging antibiotic resistance
Vaccination may be the greatest public health achievement of our time. As antibiotic resistance becomes more prevalent among pathogenic bacteria, vaccines will become even more important, however, many vaccines being developed only work against a narrow range of bacteria, even within a single genus or species, due to being ?serotype-specific.? To overcome this limitation, we have developed a new vaccine strategy that provides protection across serotype, strain and species boundaries. This nanoparticle-antigen platform will provide broad protection against pathogenic Shigella, Salmonella and Pseudomonas. Furthermore, it will provide preventative measure that overcomes the increasing development of antibiotic resistance in these important pathogens.
Filed on May 24, 2018.
Tell us what you know about Marcus Laird Forrest's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.